DDInter119 DDInter648
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Disopyramide
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Entrectinib may lead to a major life threatening interaction when taken with Disopyramide
Entrectinib may lead to a major life threatening interaction when taken with Macimorelin